Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Supramolecular assembly of GSK3α as a cellular response to amino acid starvation.
Hinze L, Schreek S, Zeug A, Ibrahim NK, Fehlhaber B, Loxha L, Cinar B, Ponimaskin E, Degar J, McGuckin C, Chiosis G, Eckert C, Cario G, Bornhauser B, Bourquin JP, Stanulla M, Gutierrez A. Hinze L, et al. Among authors: ibrahim nk. Mol Cell. 2022 Aug 4;82(15):2858-2870.e8. doi: 10.1016/j.molcel.2022.05.025. Epub 2022 Jun 21. Mol Cell. 2022. PMID: 35732190 Free PMC article.
Breast Cancer Brain Metastasis: A Comprehensive Review.
Raghavendra AS, Ibrahim NK. Raghavendra AS, et al. Among authors: ibrahim nk. JCO Oncol Pract. 2024 May 15:OP2300794. doi: 10.1200/OP.23.00794. Online ahead of print. JCO Oncol Pract. 2024. PMID: 38748968 Review.
Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention.
Akkoc Mustafayev FN, Liu DD, Gutierrez AM, Lewis JE, Ibrahim NK, Valero V, Booser DJ, Litton JK, Koenig K, Yu D, Sneige N, Arun BK. Akkoc Mustafayev FN, et al. Among authors: ibrahim nk. Eur J Breast Health. 2023 Oct 1;19(4):267-273. doi: 10.4274/ejbh.galenos.2023.2023-7-3. eCollection 2023 Oct. Eur J Breast Health. 2023. PMID: 37795002 Free PMC article.
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
Tsimberidou AM, Guenther K, Andersson BS, Mendrzyk R, Alpert A, Wagner C, Nowak A, Aslan K, Satelli A, Richter F, Kuttruff-Coqui S, Schoor O, Fritsche J, Coughlin Z, Mohamed AS, Sieger K, Norris B, Ort R, Beck J, Vo HH, Hoffgaard F, Ruh M, Backert L, Wistuba II, Fuhrmann D, Ibrahim NK, Morris VK, Kee BK, Halperin DM, Nogueras-Gonzalez GM, Kebriaei P, Shpall EJ, Vining D, Hwu P, Singh H, Reinhardt C, Britten CM, Hilf N, Weinschenk T, Maurer D, Walter S. Tsimberidou AM, et al. Among authors: ibrahim nk. Cancer Immunol Res. 2023 Jul 5;11(7):925-945. doi: 10.1158/2326-6066.CIR-22-0444. Cancer Immunol Res. 2023. PMID: 37172100 Free PMC article. Clinical Trial.
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Nelson BE, et al. Among authors: ibrahim nk. Cancer. 2023 Jul 15;129(14):2201-2213. doi: 10.1002/cncr.34773. Epub 2023 Apr 4. Cancer. 2023. PMID: 37016732 Clinical Trial.
144 results